跳至主要内容
临床试验/NCT05912335
NCT05912335已完成1 期

Clinical Efficiency of Xanthan Hydrogels Containing Local Anesthetics Encapsulated in Nanostructured Lipid Carries

University of Campinas, Brazil1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年6月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
Pain sensitivity assessment by Visual Analogue Scale after the puncture of the needle of the local anesthetic.

研究概览

简要总结

In a crossover, randomized, placebo-controlled, double-blind study, 40 volunteers will receive the following formulations: hydrogels containing LAs (local anesthetic) - lidocaine and prilocaine (both at 2.5%) encapsulated in CLN (XAN-CLN) or not (XAN-CLN ), EMLA (topical anesthetic available on the market) and placebo hydrogel. The formulations will be applied for 2 minutes, bilaterally on the palatal mucosa (first premolar region), in two distinct sessions. Soon after removal of the topical formulation, an AL will be performed at the region using 0.3 mL of anesthetic solution at an injection speed of 1 mL/min. Pain resulting from needle insertion and LA injection will be measured using two visual analog scales (VAS).

详细描述

Dental treatment presents numerous innovations, but the pain associated with the administration of local anesthesia (LA) continuous to be a traumatic procedure for many patients. Although we use topical anesthetics (TA) to reduce pain, the commercially available formulations are only effective in preventing the pain of the needle puncture.

This project aims to evaluate the clinical efficacy of xanthan-based hydrogels (2%) containing LAs encapsulated in nanostructured lipid carriers (CLN), reducing pain during puncture and injection of LA in the palatine mucosa. In a crossover, randomized, placebo-controlled, double-blind study, 40 volunteers will receive the following formulations: hydrogels containing LAs - lidocaine and prilocaine (both at 2.5%) encapsulated in CLN (XAN-CLN) or not (XAN-CLN ), EMLA and placebo hydrogel. The formulations will be applied for 2 minutes, bilaterally on the palatal mucosa (first premolar region), in two distinct sessions. Soon after the removal of the topical formulation, an AL will be performed at the region using 0.3 mL of anesthetic solution at an injection speed of 1 mL/min. The computerized Morpheus® anesthetic injector will be used in order to control the variables of volume and injection speed. Pain resulting from needle insertion and LA injection will be measured using two visual analog scales (VAS). Hydrogels containing CLN are expected to have good mechanical properties and allow the permeation of LAs efficiently through the oral mucosal epithelium. In addition, they can improve the efficacy of topical anesthesia in order to perform a painless LA in the palatal mucosa.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
Double (Participant, Care Provider)

盲法说明

The participant and the applicator don't know which formulation was applied because these were named A, B, C, and D and the applicator doesn't have access to the data of which formulation was titled by each letter.

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy participants
  • No lesions in the study area
  • Have already been submitted to local anesthesia without intercurrence

排除标准

  • Used any drugs that change the pain sensibility 1 week before
  • Alcoholic

研究组 & 干预措施

Topical anesthetic available on the market - Lidocaine (2.5%), Prilocaine (2.5%)

Active Comparator

Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.

100 mg.

干预措施: Topical anesthetic (Drug)

Xanthan hydrogel 2%

Placebo Comparator

Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.

100 mg.

干预措施: Topical anesthetic (Drug)

Xanthan hydrogel (2%), Lidocaine (2.5%), Prilocaine (2.5%) in NLC

Experimental

Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.

100 mg. Local Anesthetic encapsulated in nanostructured lipid carriers (NLC)

干预措施: Topical anesthetic (Drug)

Xanthan hydrogel (2%), Lidocaine (2.5%), Prilocaine (2.5%)

Experimental

Applied at palatal mucosa (first premolar region), for 2 minutes. After that, this formulation will be removed.

100 mg.

干预措施: Topical anesthetic (Drug)

结局指标

主要结局

Pain sensitivity assessment by Visual Analogue Scale after the puncture of the needle of the local anesthetic.

时间窗: 2 minutes

The blind investigator evaluated the values obtained on VAS, with a rule, the left far end mean 0, for no pain at all and the right far end mean 100 for maximum pain. Therefore, a a higher score means a worse outcome.

次要结局

  • Pain sensitivity assessment by Visual Analogue Scale after the injection of the local anesthetic.(2 minutes)

研究者

发起方
University of Campinas, Brazil
申办方类型
Other
责任方
Principal Investigator
主要研究者

Michelle Franz Montan Braga Leite, DDS, MSc, PhD

Principal Investigator

University of Campinas, Brazil

研究点 (1)

Loading locations...

相似试验